Specify a stock or a cryptocurrency in the search bar to get a summary
Verici Dx Plc
VRCIVerici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom. Address: Avon House, Cardiff, United Kingdom, CF64 2EZ
Analytics
WallStreet Target Price
53.31 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VRCI
Dividend Analytics VRCI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VRCI
Stock Valuation VRCI
Financials VRCI
Results | 2019 | Dynamics |